Lower serum triglyceride level is a risk factor for in-hospital and late major adverse events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention- a cohort study

BMC Cardiovascular Disorders

Kuo-Yang Wang¹  Chia-Ning Liu⁴  Chieh-Shou Su³  Hung-Yun Ho²  Wen-Lieng Lee³  Hui-Chin Lai³  Tsun-Jui Liu³  Yu-Tsung Cheng² 

[1] Chung-Shan Medical University School of Medicine, Taichung, Taiwan;Cardiovascular Center and Department of Anesthesiology, Taichung Veterans General Hospital, Taichung, Taiwan;Departments of Medicine and Surgery, Yang-Ming University School of Medicine, Taipei, Taiwan;Taipei First Girls High School, Taipei, Taiwan

关键词: Outcome;    Restenosis;    Revascularization;    Coronary;    Myocardial infarction;    Triglyceride;   

Others  :  1088430
DOI  :  10.1186/1471-2261-14-143

 received in 2014-08-18, accepted in 2014-10-06,  发布年份 2014

【 摘 要 】

Background

Whether serum triglyceride level correlates with clinical outcomes of patients with ST segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI) remains unclear.

Methods

From June 2008 to February 2012, all patients with STEMI who were treated with pPCI in this tertiary referral hospital and then had fasting lipid profiles measured within 24 hours were included and dichotomized into lower- (≦150 mg/dl) and higher-triglyceridemic (>150 mg/dl) groups. Baseline characteristics, in-hospital outcomes, and late major adverse cardiovascular events (MACE) were compared in-between. Independent predictors for in-hospital death and late adverse events were identified by multivariate logistic and Cox regression analyses.

Results

A total of 247 patients were enrolled, including 163 lower-triglyceridemic and 84 higher-triglyceridemic subjects. The angiographic characteristics, pPCI results and in-hospital outcomes were similar between the two groups. However, multivariate logistic analysis identified triglyceride level as a negative predictor for in-hospital death (OR 0.963, 95% CI 0.931-0.995, p = 0.023). At follow-up for a mean period of 1.23 to 1.40 years, compared with the high-triglyceridemic group, low-triglyceridemic patients had fewer cumulative incidences of target vessel revascularization (TVR) (21.7% vs. 9.5%, p = 0.011) and overall MACE (26.1% vs. 11.9%, p = 0.0137). Cox regression analysis confirmed serum triglyceride as a negative predictor for TVR and overall MACE.

Conclusions

Serum triglyceride level inversely correlates with in-hospital death and late outcomes in patients with STEMI treated with pPCI. Thus, when managing such patients, a high serum triglyceride level can be regarded as a benign factor but not a target for aggressive therapy.

【 授权许可】

   
2014 Cheng et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, et al.: Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation 2012, 125(1):e2-e220.
• [2]O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, et al.: 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 61(4):e78-e140.
• [3]Figueras J, Alcalde O, Barrabes JA, Serra V, Alguersuari J, Cortadellas J, Lidon RM: Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation 2008, 118(25):2783-2789.
• [4]Perers E, Caidahl K, Herlitz J, Karlson BW, Karlsson T, Hartford M: Treatment and short-term outcome in women and men with acute coronary syndromes. Int J Cardiol 2005, 103(2):120-127.
• [5]Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46(8):1405-1410.
• [6]Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G: Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007, 49(12):1272-1278.
• [7]Hokanson JE, Austin MA: Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3(2):213-219.
• [8]Kannel WB, Vasan RS: Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009, 24(4):345-350.
• [9]Eberly LE, Stamler J, Neaton JD: Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003, 163(9):1077-1083.
• [10]Carlson LA, Bottiger LE, Ahfeldt PE: Risk factors for myocardial infarction in the Stockholm prospective study. A 14-year follow-up focussing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979, 206(5):351-360.
• [11]Weir CJ, Sattar N, Walters MR, Lees KR: Low triglyceride, not low cholesterol concentration, independently predicts poor outcome following acute stroke. Cerebrovasc Dis 2003, 16(1):76-82.
• [12]Pikija S, Trkulja V, Juvan L, Ivanec M, Duksi D: Higher On-admission Serum Triglycerides Predict Less Severe Disability and Lower All-cause Mortality after Acute Ischemic Stroke. J Stroke Cerebrovasc Dis 2013, 22(7):e15-e24.
• [13]Li W, Liu M, Wu B, Liu H, Wang LC, Tan S: Serum lipid levels and 3-month prognosis in Chinese patients with acute stroke. Adv Ther 2008, 25(4):329-341.
• [14]Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E: TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000, 102(17):2031-2037.
• [15]Assmann G, Schulte H, von Eckardstein A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996, 77(14):1179-1184.
• [16]Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U: Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation 1999, 100(5):475-482.
• [17]Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115(4):450-458.
• [18]Wilson PW, Anderson KM, Castelli WP: Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: the Framingham offspring study. Am J Med 1991, 90(1):11-16.
• [19]Pocock SJ, Shaper AG, Phillips AN: Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ 1989, 298(6679):998-1002.
• [20]Grundy SM, Vega GL: Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992, 152(1):28-34.
• [21]Gandotra P, Miller M: The role of triglycerides in cardiovascular risk. Curr Cardiol Rep 2008, 10(6):505-511.
• [22]Steinberg D: Building the Basic Science Foundation. In The Cholesterol Wars: The Cholesterol Skeptics vs the Preponderance of Evidence. Edited by Steinberg D. New York: Elsevier Ltd; 2007:78.
• [23]Scott MG, Diane B, Luther TC, Richard SC, Margo AD, James H, Donald BH, Roger I, Russell VL, Patrick MB, James MM, Richard CP, Neil JS, Linda VH: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
• [24]Talayero BG, Sacks FM: The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011, 13(6):544-552.
• [25]Khawaja OA, Hatahet H, Cavalcante J, Khanal S, Al-Mallah MH: Low admission triglyceride and mortality in acute coronary syndrome patients. Cardiol J 2011, 18(3):297-303.
• [26]Windler E, Ewers-Grabow U, Thiery J, Walli A, Seidel D, Greten H: The prognostic value of hypocholesterolemia in hospitalized patients. Clin Investig 1994, 72(12):939-943.
• [27]Volpato S, Zuliani G, Guralnik JM, Palmieri E, Fellin R: The inverse association between age and cholesterol level among older patients: the role of poor health status. Gerontology 2001, 47(1):36-45.
• [28]Noel MA, Smith TK, Ettinger WH: Characteristics and outcomes of hospitalized older patients who develop hypocholesterolemia. J Am Geriatr Soc 1991, 39(5):455-461.
• [29]Richartz BM, Radovancevic B, Frazier OH, Vaughn WK, Taegtmeyer H: Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. Cardiology 1998, 89(3):184-188.
• [30]Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC: Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002, 8(4):216-224.
• [31]Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361(9351):13-20.
• [32]Inoue T, Uchida T, Yaguchi I, Sakai Y, Takayanagi K, Morooka S: Stent-induced expression and activation of the leukocyte integrin Mac-1 is associated with neointimal thickening and restenosis. Circulation 2003, 107(13):1757-1763.
• [33]Veinot JP, Edwards WD, Camrud AR, Jorgenson MA, Holmes DR Jr, Schwartz RS: The effects of lovastatin on neointimal hyperplasia following injury in a porcine coronary artery model. Can J Cardiol 1996, 12(1):65-70.
• [34]Petronio AS, Amoroso G, Limbruno U, Papini B, De Carlo M, Micheli A, Ciabatti N, Mariani M: Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J 2005, 149(3):520-526.
• [35]Lerakis S, El-Chami MF, Patel AD, Veledar E, Alexopoulos E, Zacharoulis A, Triantafyllou A: Effect of lipid levels and lipid-lowering therapy on restenosis after coronary artery stenting. Am J Med Sci 2006, 331(5):270-273.
• [36]Oi K1, Shimokawa H, Hirakawa Y, Tashiro H, Nakaike R, Kozai T, Ohzono K, Yamamoto K, Koyanagi S, Okamatsu S, Tajimi T, Kikuchi Y, Takeshita A: Postprandial increase in plasma concentrations of remnant-like particles: an independent risk factor for restenosis after percutaneous coronary intervention. J Cardiovasc Pharmacol 2004, 44(1):66-73.
• [37]Kato T, Inoue T, Inagaki H, Hashimoto S, Hikichi Y, Tanaka A, Isobe M, Node K: Remnant-like lipoprotein particle level and insulin resistance are associated with in-stent restenosis in patients with stable angina. Coron Artery Dis 2007, 18(4):319-322.
• [38]Bermudez B, Lopez S, Pacheco YM, Villar J, Muriana FJ, Hoheisel JD, Bauer A, Abia R: Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery. Cardiovasc Res 2008, 79(2):294-303.
• [39]Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123(20):2292-2333.